A chromone thiazolium dione compound, a preparation method thereof, a pharmaceutical composition and application thereof

By developing cromolynthiazoldione compounds to inhibit PTP1B enzyme and restore insulin signaling, the problem of existing drugs being unable to control blood sugar has been solved, achieving effective treatment and prevention of diabetes.

CN116693520BActive Publication Date: 2026-07-14WUYI UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310525787.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2026-07-14
Estimated Expiration
2043-05-10

AI Technical Summary

Technical Problem

Existing diabetes medications are ineffective at inhibiting protein tyrosine phosphatase 1B (PTP1B), leading to insulin signal inactivation and an inability to effectively control blood sugar levels.

Method used

To develop a chromonethiazole dione compound that can restore the insulin signaling pathway and lower blood glucose levels by inhibiting PTP1B enzyme activity.

Benefits of technology

Cromolynthiazolidinediones exhibit strong PTP1B inhibitory activity, which can treat and prevent diabetes, restore insulin sensitivity, and control blood glucose levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116693520B_ABST
    Figure CN116693520B_ABST
Patent Text Reader

Abstract

The application discloses a chromone thiazole diketone compound, a preparation method, a pharmaceutical composition and application thereof, and the chromone thiazole diketone compound has a compound as shown in formula (I): wherein R is selected from substituted or unsubstituted C 6~12 Aryl of the application. A series of chromone thiazole diketone compounds are designed and synthesized, and the compounds show strong PTP1B inhibition, and can be used as PTP1B enzyme inhibitors for treating or preventing diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of organic synthesis technology, and in particular to a chromonethiazolidinedione compound, its preparation method, pharmaceutical composition, and application. Background Technology

[0002] On December 6, 2021, the International Diabetes Federation (IDF) released the "IDF World Diabetes Atlas (10th Edition)," which included nine key data points about diabetes worldwide in 2021: 1 in 10 adults aged 20-79 has diabetes, totaling 537 million; 1 in 2 people with diabetes remains undiagnosed, totaling 240 million; 3 in 4 people with diabetes live in low- or middle-income countries or regions; 1 in 18 adults aged 20-79 has impaired fasting glucose, totaling 319 million; 1 in 6 live births is affected by gestational diabetes, totaling 21 million, with 80% of these children's mothers having gestational diabetes; 1.2 million children and adolescents under the age of 20 have type 1 diabetes; 1 in 9 adults aged 20-79 has impaired glucose tolerance, totaling 541 million; 9% of global health expenditure is spent on diabetes, totaling US$966 million; and 6.7 million people have died from diabetes.

[0003] Diabetes mellitus is a chronic metabolic disorder caused by insufficient insulin secretion or damage to pancreatic beta cells, leading to elevated blood glucose levels. Long-term high blood glucose levels due to diabetes can cause a series of complications. For example, increased blood glucose levels can lead to many microvascular and macrovascular complications. Microvascular complications include retinopathy, cataracts, nephropathy, and neuropathy, while macrovascular complications include stroke, cardiovascular disease, coronary artery disease, cerebrovascular disease, and diabetic foot, which can lead to amputation in severe cases. Currently, the main hypoglycemic drugs used clinically include sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and non-sulfonylurea insulin secretagogues.

[0004] Among the PTP family members, protein tyrosine phosphatase 1B (PTP1B) plays a negative regulatory role in the insulin and leptin signaling systems and has been shown to be an important molecular target for the potential treatment of type 2 diabetes. Numerous studies in human and animal models have demonstrated that insulin resistance in type 2 diabetes is achieved through increased PTP activity and expression levels of PTP family members. Insulin binding to the insulin receptor (IR) induces a conformational change, thereby activating the receptor tyrosine kinase structure and triggering intracytoplasmic insulin signaling transduction. Activated receptors at multiple tyrosine residues undergo autophosphorylation, resulting in insulin receptor substrate 1 (IRS1), which in turn activates the PI3K and Akt pathways. Subsequently, glucose transporter type 4 (GLUT4) is transported to the cell surface and takes up cellular glucose. PTP1B catalyzes the dephosphorylation of phosphorylated IR and IRS1 by tyrosine residues (pY1162 / pY1163), thereby inactivating and terminating IR signaling. According to Johnson's research, leptin binding to its receptor leads to phosphorylation of Janus kinase 2 (JAK2), thereby activating the JAK2 signal transducer and transcription 3 (STAT3). STAT3 induces gene regulation to reduce the transcription of acetyl-CoA carboxylase and malonyl-CoA and fatty acid synthesis, while increasing fatty acid oxidation. Therefore, protein tyrosine phosphatase 1B (PTP1B) is considered an important target for the treatment of diabetes and obesity, and could potentially serve as a target for drug therapy.

[0005] Therefore, it is necessary to develop a compound that acts on protein tyrosine phosphatase 1B to treat diabetes. Summary of the Invention

[0006] The present invention aims to at least solve one of the technical problems existing in the prior art. To this end, the first aspect of the present invention provides a chromonethiazolidinedione compound, which has PTP1B inhibitory activity and can treat and / or prevent diabetes by inhibiting PTP1B.

[0007] A second aspect of the present invention also provides a method for preparing chromonethiazole dione compounds.

[0008] A third aspect of the present invention also provides a pharmaceutical composition.

[0009] A fourth aspect of the present invention also provides a protein tyrosine phosphatase 1B inhibitor.

[0010] The fifth aspect of the present invention also provides an application of a chromonethiazole dione compound.

[0011] According to a first aspect of the present invention, a chromonethiazole dione compound or a pharmaceutically acceptable salt thereof is provided, said chromonethiazole dione compound having a compound as shown in formula (I):

[0012] ;

[0013] Wherein, R is selected from substituted or unsubstituted C. 6~12 Aryl groups.

[0014] The chromonethiazolidinone compounds or their pharmaceutically acceptable salts according to embodiments of the present invention have at least the following beneficial effects:

[0015] This invention designs and synthesizes a series of chromonethiazole dione compounds that exhibit strong PTP1B inhibitory activity and can be used as PTP1B enzyme inhibitors for the treatment or prevention of diabetes.

[0016] According to some embodiments of the present invention, R is selected from substituted or unsubstituted phenyl groups, the substitution is monosubstituted or polysubstituted, and the substituted group is selected from halogens, C 1~6 alkyl, C 1~6 alkoxy, C 1~6 Halogenated alkyl, C 1~6 The halogenated alkoxy, nitro, cyano or phenyl groups.

[0017] According to some embodiments of the present invention, the R is selected from the following groups:

[0018] .

[0019] According to a second aspect of the present invention, a method for preparing the above-described chromonethiazole dione compounds is provided, comprising the following steps:

[0020] Intermediate 3, A copper catalyst and a reducing agent undergo a cycloaddition reaction to yield chromonethiazole dione compounds;

[0021] The structural formula of intermediate 3 is as follows:

[0022] .

[0023] According to some embodiments of the present invention, the cycloaddition reaction is carried out at room temperature.

[0024] According to some embodiments of the present invention, the reaction time of the cycloaddition reaction is 8 to 16 hours.

[0025] According to some embodiments of the present invention, the copper catalyst is at least one of copper sulfate pentahydrate, copper iodide, or copper bromide.

[0026] According to some embodiments of the present invention, the reducing agent includes at least one of sodium ascorbate or metallic copper.

[0027] According to some embodiments of the present invention, the intermediate 3 is prepared by the following method:

[0028] Intermediate 2 and thiazolidinedione undergo an aldol condensation reaction to generate intermediate 3;

[0029] The structural formula of intermediate 2 is as follows:

[0030] .

[0031] According to some embodiments of the present invention, the intermediate 2 is prepared by the following method:

[0032] Intermediate 1 was subjected to a Vilsmeier–Haack reaction to obtain intermediate 2;

[0033] The structural formula of intermediate 1 is as follows:

[0034] .

[0035] According to some embodiments of the present invention, the intermediate 1 is prepared by the following method:

[0036] 2,4-Dihydroxyacetophenone, propargyl bromide, a base, and an organic solvent are mixed and reacted to generate intermediate 1.

[0037] According to some embodiments of the present invention, the alkali is at least one selected from potassium carbonate, sodium carbonate, cesium carbonate, or sodium hydroxide.

[0038] According to some embodiments of the present invention, the organic solvent is acetone, dichloromethane, or acetonitrile.

[0039] A third aspect of the present invention provides a pharmaceutical composition comprising the above-described chromonethiazolidinedione compound or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

[0040] A fourth aspect of the present invention provides a protein tyrosine phosphatase 1B inhibitor, comprising the above-described chromonethiazolidinedione compounds or pharmaceutically acceptable salts thereof.

[0041] The fifth aspect of this invention provides the use of the above-described chromonethiazolidinedione compounds in the preparation of products for the treatment and / or prevention of diabetes.

[0042] According to some embodiments of the present invention, the product is a pharmaceutical product.

[0043] Definitions and general terms

[0044] "C replaced or not replaced"6~12 "Aryl" indicates an all-carbon monocyclic or fused polycyclic group with a fully conjugated π-electron system; and the total number of carbon atoms is 6 to 12. In addition, at least one H in the aryl group may be replaced by the corresponding group defined herein.

[0045] “C 1~6 "alkyl" indicates an alkyl group with a total number of 1-6 carbon atoms, including C64. 1-6 straight-chain alkyl, C 1-6 Branched alkyl groups and C 3-6 The cycloalkyl group can be, for example, a straight-chain alkyl group with a total number of carbon atoms of 1, 2, 3, 4, 5 or 6, a branched-chain alkyl group with a total number of carbon atoms of 1, 2, 3, 4, 5 or 6, or a cycloalkyl group with a total number of carbon atoms of 3, 4, 5 or 6, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, cyclopropyl, methylcyclopropyl, ethylcyclopropyl, cyclopentyl, methylcyclopentyl, cyclohexyl, etc.

[0046] “C 1~6 "Alkoxy" refers to alkoxy groups with a total number of carbon atoms of 1-6, including C1-6 straight-chain alkoxy groups, C1-6 branched-chain alkoxy groups, and C2-6 cycloalkoxy groups. For example, it can be a straight-chain alkoxy group with a total number of carbon atoms of 1, 2, 3, 4, 5, or 6; a branched-chain alkoxy group with a total number of carbon atoms of 1, 2, 3, 4, 5, or 6; or a cycloalkoxy group with a total number of carbon atoms of 2, 3, 4, 5, or 6, such as methoxy, ethoxy, n-propoxy, isopropoxy, etc.

[0047] “C 1~6 "Halogenated alkyl" refers to an alkyl group with a total number of carbon atoms of 1 to 6, preferably an alkyl group as defined above, which is substituted by one or more identical or different halogen atoms, for example... CH2Cl, CF3 CCl3, CH2CF3, CH2CCl3, etc.

[0048] “C 1~6 "Haloalkoxy" refers to an alkoxy group with a total number of carbon atoms of 1 to 6, preferably an alkoxy group as defined above, which is substituted by one or more identical or different halogen atoms.

[0049] The structural formula in this invention appears as " "" indicates the linking site of a functional group.

[0050] In this invention, room temperature refers to a temperature between 20 and 28°C.

[0051] The term "pharmaceutically acceptable" as used in this invention refers to a substance that is acceptable from a toxicological point of view for pharmaceutical use and will not adversely interact with the active ingredient.

[0052] The pharmaceutically acceptable excipients used in this invention include any solvent, solid excipient, diluent, binder, disintegrant, or other liquid excipient, dispersant, flavoring agent or suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid binder, flow aid or lubricant, etc., suitable for the specific target dosage form. As described in the following literature: In Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York, the content of this literature shows that different excipients can be used in the formulation of pharmaceutically acceptable compositions and their known methods of preparation. Except for any conventional excipients that are incompatible with the compounds of the present invention, such as any adverse biological effects produced or interactions with any other component of a pharmaceutically acceptable composition that occur in a harmful manner, their use is also within the scope of this invention.

[0053] Substances that are pharmaceutically acceptable excipients include, but are not limited to, ion exchangers; aluminum; aluminum stearate; lecithin; serum proteins, such as human serum albumin; buffering substances such as phosphates; glycine; sorbic acid; potassium sorbate; mixtures of partial glycerides of saturated vegetable fatty acids; water; salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; polyacrylates; waxes; polyethylene-polyoxypropylene-blocking polymers; lanolin; sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as carboxymethyl cellulose. Sodium thiosulfate, ethyl cellulose and cellulose acetate; gum powder; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic salts; Ringer's solution; ethanol; phosphate buffer solution; and other non-toxic and suitable lubricants such as sodium lauryl sulfate and magnesium stearate; colorants; release agents; coatings; sweeteners; flavorings; fragrances; preservatives and antioxidants.

[0054] The pharmaceutical composition of the compounds of this invention can be administered in unit dose form. The dosage form can be a liquid or a solid. Liquid dosage forms can be true solutions, colloids, microparticles, or suspensions. Other dosage forms include tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, emulsions, granules, suppositories, and lyophilized powder injections.

[0055] Oral tablets and capsules may contain excipients such as binders, like syrup, gum arabic, sorbitol, astragalus gum, or polyvinylpyrrolidone; fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants such as magnesium stearate, talc, polyethylene glycol, or silica; disintegrants such as potato starch; or acceptable wetting agents such as sodium lauryl sulfate. Tablets may be coated using pharmaceutically known methods.

[0056] Oral liquids can be formulated as suspensions, solutions, emulsions, syrups, or elixirs of hydrated oils, or as dry products to be replenished with water or other suitable media before use. These liquid formulations may contain conventional additives such as suspending agents, sorbitol, cellulose methyl ether, glucose syrup, gelling agents, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, hydrogenated edible oils, emulsifiers such as lecithin, sorbitan monooleate, and gum arabic; or non-aqueous carriers (which may contain edible oils such as almond oil), oils such as glycerin, ethylene glycol, or ethanol; preservatives such as methylparaben or propylparaben, and sorbic acid. Flavorings or colorings may be added if desired.

[0057] Other features and advantages of the invention will be set forth in the description which follows, and will be apparent in part from the description, or may be learned by practicing the invention. Attached Figure Description

[0058] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which:

[0059] Figure 1 Example 31 of this invention provides a half-maximal inhibitory concentration (IC50) of chromonethiazolidinedione compound I-18 as a PTP1B inhibitor in vitro.

[0060] Figure 2 The above is a diagram showing the in vitro enzyme kinetics of PTP1B by compound I-18, a chromonethiazole dione, as a PTP1B enzyme inhibitor in Example 32 of this invention.

[0061] Figure 3 This is a substrate kinetic diagram of the PTP1B enzyme in vitro using chromonethiazole dione compound I-18 as a PTP1B inhibitor in Example 33 of the present invention. Detailed Implementation

[0062] The following are specific embodiments of the present invention, and the technical solutions of the present invention will be further described in conjunction with the embodiments, but the present invention is not limited to these embodiments.

[0063] Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in this technical field.

[0064] This invention provides a general method for preparing chromonethiazole dione compounds, the general preparation method of which is as follows:

[0065] Starting with 2,4-dihydroxyacetophenone, it reacts with propargyl bromide to generate intermediate 1. Intermediate 1 then undergoes a Vilsmeier-Haack reaction to prepare intermediate 2. Intermediate 2 then undergoes an aldol condensation with a thiazolidinedione to generate intermediate 3. Finally, intermediate 3 is reacted with... A cycloaddition reaction occurs to give the target product; the reaction equation is shown below:

[0066] ;

[0067] The specific steps are as follows:

[0068] A mixture of 2,4-dihydroxyacetophenone (1.0 g, 6.6 mmol), propargyl bromide (515 μL, 6.6 mmol), and potassium carbonate (0.91 g, 6.6 mmol) was added to 15 mL of acetone solution and heated under reflux at 60 °C for 6 h. The reaction was monitored by TLC. After the reaction was complete, the mixture was hot-filtered, and the solvent was evaporated under reduced pressure. The resulting crude intermediate 1 did not require purification and was directly used for the next reaction.

[0069] Under anhydrous and oxygen-free conditions, phosphorus oxychloride (1.9 mL, 20.4 mmol) was added dropwise to a 5 mL solution of dry DMF that was stirred and cooled (0–5 °C). The reaction mixture was then heated to room temperature and stirred for 30 min. Intermediate 1 (1.9 g, 10.0 mmol), dissolved in DMF, was slowly added dropwise to the reaction mixture under ice bath conditions. After stirring for 30 min, the mixture was gradually brought back to room temperature and maintained for 4 h. After the reaction was complete, the mixture was poured into crushed ice and stirred for 4 h. The red solid precipitate was filtered off, and the mixture was washed with water and a small amount of ethyl acetate to obtain intermediate 2.

[0070] Intermediate 2 (5.8 g, 25.2 mmol), thiazolidinedione (3.0 g, 25.2 mmol), and sodium acetate (2 g, 25.2 mmol) were added sequentially to 50 mL of glacial acetic acid. The mixture was then stirred at 100 °C, and the solid was observed to gradually dissolve until the reaction system turned red. A solid precipitated after approximately 4 h of reaction. After confirming the reaction was complete by TLC monitoring, the mixture was cooled to room temperature and the solid precipitate was filtered off. The crude product was washed with a small amount of glacial ethanol to obtain red solid intermediate 3.

[0071] Add intermediate 3 (150.0 mg, 0.5 mmol) to a 15 mL reaction tube. Copper sulfate pentahydrate (130.0 mg, 0.75 mmol), copper sulfate pentahydrate (15.0 mg, 0.06 mmol), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (26.0 mg, 0.05 mmol), and sodium ascorbate (53.0 mg, 0.28 mmol) were added to a tetrahydrofuran / water mixture (2.5:1, 4 mL) as a solvent. The mixture was stirred overnight at room temperature in the dark. After the reaction was complete, the solid was filtered off and recrystallized from DMF to obtain the final product.

[0072] Examples 1-30

[0073] Examples 1-30 provide a series of chromonethiazole dione compounds, which can be prepared using the general preparation methods described above. Their general structural formulas and R groups are as follows:

[0074]

[0075] Table 1. Structural formulas of the R group

[0076]

[0077] The structures of the compounds prepared in Examples 1-30 were characterized by NMR, MS, and melting point. The following are the characterization results of each compound, including its properties, yield, NMR, and mass spectrometry:

[0078]

[0079] ( Ⅰ -1,C 23 H 16 N 4 O 5 S) . White sold; Yield 77%; mp 277.3 – 280.8 °C; 1 H NMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.74 (s, 1H), 8.36 (s, 1H), 8.01 (d, J =8.8Hz, 1H), 7.64 (s, 1H), 7.43 – 7.29 (m, 6H), 7.17 (dd, J =8.9, 2.3 Hz, 1H), 5.63(s, 2H), 5.33 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 173.97, 163.04, 157.14,142.03, 135.95, 128.80, 128.21, 128.01, 127.06, 125.17, 116.92, 115.93,101.98, 61.98, 52.89. HRMS (ESI) [M+H] + calcd. for C 23 H 16 N4O5S: 461.0912; found:461.0914.

[0080]

[0081] ( Ⅰ -2,C 23 H 15 FN 4 O 5 S) . White sold; Yield 65%; m.p. 265.3 – 268.8 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.75 (s, 1H), 8.36 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.60 (s, 1H), 7.41 (dd, J =8.2, 5.0 Hz, 3H), 7.25 – 7.13 (m, 3H), 5.62(s, 2H), 5.32 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 174.00, 163.05, 162.90,160.96, 160.54, 157.14, 142.05, 132.22, 132.20, 130.43, 130.36, 129.86,127.08, 125.09, 116.90, 115.95, 115.74, 115.57, 101.98, 61.98, 52.09. HRMS(ESI) [M+H] + calcd. for C 23 H 15 FN4O5S: 479.0820; found: 479.0821.

[0082]

[0083] ( Ⅰ -3,C 23 H 15 FN 4 O 5 S) . White sold; Yield 70%; m.p. 276.2 – 279.1 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.73 (s, 1H), 8.40 (s, 1H), 8.01 (d, J=8.9Hz, 1H), 7.65 (s, 1H), 7.47 – 7.37 (m, 2H), 7.22 – 7.12 (m, 4H), 5.66 (s,2H), 5.34 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 173.95, 163.09, 163.00, 161.15,157.13, 142.13, 138.61, 138.55, 130.93, 130.86, 127.05, 125.33, 124.10,124.08, 116.93, 115.92, 115.16, 114.99, 114.94, 114.77, 101.97, 61.94, 52.19.HRMS (ESI) [M+H] + calcd. for C 23 H 15 FN4O5S: 479.0820; found: 479.0817.

[0084]

[0085] ( Ⅰ -4,C 23 H 15 FN 4 O 5 S) . White sold; Yield 67%; m.p. 251.3 – 253.3 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.71 (s, 1H), 8.35 (s, 1H), 8.00 (d, J =8.9Hz, 1H), 7.64 (s, 1H), 7.46 – 7.34 (m, 3H), 7.24 (dt, J =15.2, 8.4 Hz, 2H),7.15 (dd, J =8.9, 2.3 Hz, 1H), 5.69 (s, 2H), 5.32 (s, 2H). 13C NMR (126 MHz,DMSO) δ 173.89, 162.96, 161.06, 159.10, 157.09, 141.97, 130.83, 130.79,130.76, 127.00, 125.36, 124.85, 124.82, 122.74, 122.62, 116.89, 115.85,115.71, 115.54, 101.90, 61.85, 46.99, 46.96. HRMS (ESI) [M+H] + calcd. forC 23 H 15 FN4O5S: 479.0820; found: 479.0819.

[0086]

[0087] ( Ⅰ -5,C 23 H 15 ClN 4 O 5 S) . White sold; Yield 68%; m.p. 280.7 – 283.2 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.76 (s, 1H), 8.37 (s, 1H), 8.01 (d, J =8.9 Hz, 1H), 7.60 (s, 1H), 7.45 (d, J =8.1 Hz, 2H), 7.40 (d, J =2.4 Hz, 1H), 7.35(d, J =8.2 Hz, 2H), 7.17 (dd, J =8.9, 2.4 Hz, 1H), 5.63 (s, 2H), 5.33 (s, 2H). 13 CNMR (126 MHz, DMSO) δ 173.98, 163.04, 160.56, 157.13, 142.07, 134.93, 132.94,129.99, 128.81, 127.08, 125.21, 116.90, 115.94, 101.99, 61.97, 52.08. HRMS(ESI) [M+H]+ calcd. for C 23 H 15 ClN4O5S: 495.0524; found: 495.0523.

[0088]

[0089] ( Ⅰ -6,C 23 H 15 ClN 4 O 5 S) . White sold; Yield 62%; m.p. 275.7 – 279.2 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.73 (s, 1H), 8.40 (s, 1H), 8.01 (d, J =8.9 Hz, 1H), 7.62 (s, 1H), 7.45 – 7.36 (m, 4H), 7.32 – 7.25 (m, 1H), 7.16(dd, J =9.0, 2.4 Hz, 1H), 5.65 (s, 2H), 5.34 (s, 2H). 13 C NMR (126 MHz, DMSO) δ173.95, 162.98, 157.12, 138.31, 133.29, 130.74, 128.20, 127.86, 127.06,126.74, 125.35, 116.92, 115.92, 101.97, 61.93, 52.10. HRMS (ESI) [M+H] + calcd.for C 23 H 15 ClN4O5S: 495.0524; found: 495.0522.

[0090]

[0091] ( Ⅰ -7,C 23 H 15 ClN 4 O 5 S). White sold; Yield 67%; m.p. 223.8 – 227.3 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.63 (d, J =21.5 Hz, 1H), 8.35 (s, 1H),8.02 (d, J =8.9 Hz, 1H), 7.83 (s, 1H), 7.53 (dd, J =7.7, 1.5 Hz, 1H), 7.45 – 7.34(m, 3H), 7.26 (dd, J =7.4, 1.9 Hz, 1H), 7.17 (dd, J =8.9, 2.3 Hz, 1H), 5.74 (s,2H), 5.34 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 173.93, 162.94, 157.17, 133.14,132.66, 130.59, 130.32, 129.65, 127.74, 127.03, 125.62, 117.01, 115.87,101.95, 61.88, 50.68. HRMS (ESI) [M+H] + calcd. for C 23 H 15 ClN4O5S: 495.0524;found: 495.0525.

[0092]

[0093] ( Ⅰ -8,C 23 H 15 BrN 4 O 5 S) . White sold; Yield 71%; m.p. 286.6 – 289.4 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.71 (s, 1H), 8.36 (s, 1H), 8.02 (d, J =8.9 Hz, 1H), 7.67 (s, 1H), 7.58 (d, J=8.3 Hz, 2H), 7.39 (d, J =2.3 Hz, 1H), 7.29(d, J =8.1 Hz, 2H), 7.16 (dd, J =8.9, 2.4 Hz, 1H), 5.62 (s, 2H), 5.33 (s, 2H). 13 CNMR (126 MHz, DMSO) δ 173.95, 162.98, 157.18, 135.34, 131.72, 130.28, 127.06,125.23, 121.49, 115.88, 101.95, 67.01, 61.94, 52.13. HRMS (ESI) [M+H] + calcd.for C 23 H 15 BrN4O5S: 536.9874; found: 536.9876.

[0094]

[0095] ( Ⅰ -9,C 23 H 15 BrN 4 O 5 S) . White sold; Yield 75%; m.p. 264.4 – 267.1 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.72 (s, 1H), 8.40 (s, 1H), 8.01 (d, J =8.9 Hz, 1H), 7.87 – 7.55 (m, 1H), 7.53 (d, J =1.8 Hz, 2H), 7.39 (d, J =2.3 Hz,1H), 7.37 – 7.29 (m, 2H), 7.17 (dd, J =8.9, 2.3 Hz, 1H), 5.64 (s, 2H), 5.34 (s,2H). 13C NMR (126 MHz, DMSO) δ 173.94, 162.98, 157.13, 138.55, 131.09, 131.01,130.73, 127.13, 127.06, 125.34, 121.85, 116.95, 115.91, 101.97, 61.93, 52.03.HRMS (ESI) [M+H] + calcd. for C 23 H 15 BrN4O5S: 536.9874; found: 536.9877.

[0096]

[0097] ( Ⅰ -10,C 23 H 15 BrN 4 O 5 S) . White sold; Yield 70%; m.p. 270.1 – 272.4 °C; 1 HNMR (500 MHz, DMSO) δ 12.63 – 12.23 (m, 1H), 8.70 (s, 1H), 8.33 (s, 1H), 8.00(d, J =8.8 Hz, 1H), 7.68 (d, J =7.9 Hz, 2H), 7.46 – 7.35 (m, 2H), 7.31 (t, J =7.5Hz, 1H), 7.24 – 7.11 (m, 2H), 5.71 (s, 2H), 5.34 (s, 2H). 13 C NMR (126 MHz,DMSO) δ 173.86, 162.93, 157.12, 134.71, 132.89, 130.49, 130.44, 128.25,126.99, 125.63, 122.88, 115.87, 101.93, 61.85, 52.96. HRMS (ESI) [M+H] + calcd.for C 23 H 15 BrN4O5S: 536.9874; found: 536.9875.

[0098]

[0099] ( Ⅰ -11,C 24 H 18 N 4 O 5 S) . White sold; Yield 73%; m.p. 273.2 – 276.7 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.74 (s, 1H), 8.32 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.61 (s, 1H), 7.39 (d, J =2.4 Hz, 1H), 7.22 (d, J =7.8 Hz, 2H), 7.20 –7.13 (m, 3H), 5.56 (s, 2H), 5.31 (s, 2H), 2.27 (s, 3H). 13 C NMR (126 MHz, DMSO)δ 173.97, 163.04, 157.13, 137.57, 132.94, 129.31, 128.06, 127.06, 125.02,116.89, 115.94, 101.98, 61.98, 52.70, 20.70. HRMS (ESI) [M+H] + calcd. forC 24 H 18 N4O5S: 473.0925; found: 473.0927.

[0100]

[0101] ( Ⅰ -12,C 24 H 18 N 4 O 5 S) . White sold; Yield 77%; m.p. 250.6 – 253.4 °C; 1H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.71 (s, 1H), 8.35 (s, 1H), 8.01 (d, J =8.8Hz, 1H), 7.77 (d, J =74.1 Hz, 1H), 7.38 (d, J =2.3 Hz, 1H), 7.25 (t, J =7.6 Hz,1H), 7.19 – 7.07 (m, 4H), 5.57 (s, 2H), 5.32 (s, 2H), 2.27 (s, 3H). 13 C NMR(126 MHz, DMSO) δ 173.90, 162.97, 157.12, 137.99, 135.79, 128.80, 128.67,128.52, 127.02, 125.15, 125.09, 116.93, 115.88, 101.93, 61.93, 52.86, 20.88.HRMS (ESI) [M+H] + calcd. for C 24 H 18 N4O5S: 473.0925; found: 473.0925.

[0102]

[0103] ( Ⅰ -13,C 24 H 18 N 4 O 5 S) . White sold; Yield 73%; m.p. 234.3 – 236.8 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.68 (s, 1H), 8.26 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.71 (s, 1H), 7.38 (s, 1H), 7.27 – 7.14 (m, 4H), 7.09 (d, J =7.5 Hz,1H), 5.63 (s, 2H), 5.32 (s, 2H), 2.30 (s, 3H).13 C NMR (126 MHz, DMSO) δ173.92, 162.96, 157.16, 136.32, 134.04, 130.44, 128.68, 128.37, 127.03,126.26, 125.27, 116.99, 115.89, 101.96, 61.92, 51.00, 18.62. HRMS (ESI) [M+H] + calcd. for C 24 H 18 N4O5S: 473.0925; found: 473.0926.

[0104]

[0105] ( Ⅰ -14,C 24 H 18 N 4 O 6 S) . White sold; Yield 66%; m.p. 248.8 – 250.5 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.68 (s, 1H), 8.30 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.71 (d, J =7.6 Hz, 1H), 7.38 (d, J =2.3 Hz, 1H), 7.30 (d, J =8.3 Hz, 2H),7.15 (dd, J =8.9, 2.3 Hz, 1H), 6.95 – 6.89 (m, 2H), 5.53 (s, 2H), 5.31 (s, 2H),3.73 (s, 3H). 13 C NMR (126 MHz, DMSO) δ 173.92, 162.99, 159.15, 157.17, 129.66,127.82, 127.03, 124.85, 117.00, 115.86, 114.12, 101.92, 61.95, 55.12, 52.43.HRMS (ESI) [M+H] + calcd. for C24 H 18 N4O6S: 489.0874; found: 489.0877.

[0106]

[0107] ( Ⅰ -15,C 24 H 18 N 4 O 6 S) . White sold; Yield 66%; m.p. 247.9 – 251.9 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.72 (s, 1H), 8.36 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.72 (s, 1H), 7.39 (s, 1H), 7.28 (t, J =8.2 Hz, 1H), 7.16 (d, J =8.9 Hz,1H), 6.88 (dd, J =15.6, 6.4 Hz, 3H), 5.58 (s, 2H), 5.33 (s, 2H), 3.72 (s, 3H). 13 C NMR (126 MHz, DMSO) δ 173.94, 162.98, 159.42, 157.17, 137.35, 129.94,127.04, 125.21, 120.04, 117.00, 115.90, 113.75, 113.48, 101.95, 67.00, 61.94,55.08, 52.78, 25.11. HRMS (ESI) [M+H] + calcd. for C 24 H 18 N4O6S: 489.0874; found:489.0872.

[0108]

[0109] ( Ⅰ -16,C 24 H 15 F 3N 4 O 5 S) . White sold; Yield 67%; m.p. 262.7 – 265.5 °C; 1 HNMR (500 MHz, DMSO) δ 12.44 (s, 1H), 8.63 (s, 1H), 8.41 (s, 1H), 8.02 (d, J =8.8 Hz, 1H), 7.76 (d, J =8.0 Hz, 2H), 7.52 (d, J =8.0 Hz, 2H), 7.39 (d, J =2.3 Hz,1H), 7.17 (dd, J =8.9, 2.3 Hz, 1H), 5.76 (d, J =1.7 Hz, 2H), 5.34 (s, 2H). 13 C NMR(126 MHz, DMSO) δ 173.90, 162.94, 157.24, 140.57, 128.70, 128.57, 127.06,125.76, 125.73, 125.70, 125.48, 115.84, 101.93, 61.92, 52.20. HRMS (ESI) [M+H] + calcd. for C 24 H 15 F3N4O6S: 527.0642; found: 527.0639.

[0110]

[0111] ( Ⅰ -17,C 24 H 15 F 3 N 4 O 5 S) . White sold; Yield 63%; m.p. 241.3 – 244.4 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.71 (s, 1H), 8.43 (s, 1H), 8.01 (d, J=8.9 Hz, 1H), 7.74 – 7.69 (m, 2H), 7.62 (dd, J =4.9, 1.7 Hz, 2H), 7.38 (d, J =2.4Hz, 1H), 7.16 (dd, J =9.0, 2.4 Hz, 1H), 5.75 (s, 2H), 5.34 (s, 2H). 13 C NMR (126MHz, DMSO) δ 173.93, 162.96, 157.12, 137.31, 132.23, 129.99, 129.51, 129.26,127.04, 125.38, 125.05, 125.02, 124.99, 124.96, 124.71, 124.68, 124.65,124.61, 122.89, 116.94, 115.90, 101.94, 61.91, 52.13. HRMS (ESI) [M+H] + calcd.for C 24 H 15 F3N4O6S: 527.0642; found: 527.0645.

[0112]

[0113] ( Ⅰ -18,C 24 H 15 F 3 N 4 O 5 S) . White sold; Yield 67%; m.p. 271.3 – 273.0 °C; 1 HNMR (500 MHz, DMSO) δ 12.44 (s, 1H), 8.76 (s, 1H), 8.36 (s, 1H), 8.03 (d, J =8.9 Hz, 1H), 7.82 (d, J =7.8 Hz, 1H), 7.70 (t, J =7.6 Hz, 1H), 7.60 (q, J =6.2 Hz,2H), 7.41 (d, J=2.4 Hz, 1H), 7.24 – 7.15 (m, 2H), 5.83 (s, 2H), 5.36 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 173.99, 163.03, 157.14, 141.99, 133.54, 133.22,130.42, 129.01, 127.07, 126.76, 126.52, 126.31, 126.27, 125.84, 125.22,123.04, 116.92, 115.99, 102.03, 61.92, 49.67. HRMS (ESI) [M+H] + calcd. forC 24 H 15 F3N4O6S: 527.0642; found: 527.0644.

[0114]

[0115] ( Ⅰ -19,C 24 H 15 F 3 N 4 O 6 S) . White sold; Yield 64%; m.p. 253.4 – 255.6 °C; 1 HNMR (500 MHz, DMSO) δ 12.44 (s, 1H), 8.69 (s, 1H), 8.40 (s, 1H), 8.02 (d, J =8.9 Hz, 1H), 7.71 (s, 1H), 7.47 (d, J =8.5 Hz, 2H), 7.39 (d, J =7.9 Hz, 3H), 7.17(dd, J =8.9, 2.3 Hz, 1H), 5.68 (s, 2H), 5.34 (s, 2H). 13C NMR (126 MHz, DMSO) δ174.40, 163.46, 157.67, 148.56, 135.87, 130.55, 127.54, 125.77, 121.88,116.35, 102.43, 62.42, 52.45. HRMS (ESI) [M+H] + calcd. for C 24 H 15 F3N4O6S:543.0592; found: 543.0594.

[0116]

[0117] ( Ⅰ -20,C 24 H 15 F 3 N 4 O 6 S) . White sold; Yield 69%; m.p. 242.6 – 244.8 °C;FC 1 HNMR (500 MHz, DMSO) δ 12.44 (s, 1H), 8.74 (s, 1H), 8.42 (s, 1H), 8.02 (d, J =8.9 Hz, 1H), 7.64 (s, 1H), 7.53 (t, J =8.0 Hz, 1H), 7.40 (d, J =2.4 Hz, 1H), 7.35(q, J =5.0 Hz, 3H), 7.17 (dd, J =8.9, 2.4 Hz, 1H), 5.71 (s, 2H), 5.35 (s, 2H). 13 CNMR (126 MHz, DMSO) δ 174.42, 163.46, 157.60, 148.93, 142.63, 139.06, 131.37,127.56, 127.53, 125.85, 121.48, 121.18, 120.94, 119.44, 117.39, 116.39,102.43, 62.39, 52.51. HRMS (ESI) [M+H] + calcd. for C 24 H15 F3N4O6S: 543.0592;found: 543.0594.

[0118]

[0119] ( Ⅰ -21,C 24 H 15 F 3 N 4 O 6 S) . White sold; Yield 61%; m.p. 245.3 – 246.7 °C; 1 HNMR (500 MHz, DMSO) δ 12.43 (s, 1H), 8.75 (s, 1H), 8.32 (s, 1H), 8.01 (d, J =9.0 Hz, 1H), 7.64 (s, 1H), 7.52 (td, J =7.8, 1.9 Hz, 1H), 7.46 – 7.34 (m, 4H),7.16 (dd, J =8.9, 2.4 Hz, 1H), 5.71 (s, 2H), 5.34 (s, 2H). 13 C NMR (126 MHz,DMSO) δ 173.97, 163.01, 157.14, 146.42, 141.93, 130.94, 130.61, 127.99,127.80, 127.05, 125.48, 121.08, 120.48, 119.03, 116.92, 115.98, 101.99,61.90, 47.76, 29.00. HRMS (ESI) [M+H] + calcd. for C 24 H 15 F3N4O6S: 543.0592; found:543.0593.

[0120]

[0121] ( Ⅰ -22,C 23 H 15 N 5 O 7 S). White sold; Yield 62%; m.p. 247.3 – 249.8 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.66 (d, J =13.4 Hz, 1H), 8.44 (s, 1H), 8.24(d, J =8.4 Hz, 2H), 8.01 (d, J =8.9 Hz, 1H), 7.93 – 7.60 (m, 1H), 7.54 (d, J =8.3Hz, 2H), 7.39 (d, J =2.3 Hz, 1H), 7.16 (dd, J =8.8, 2.2 Hz, 1H), 5.82 (s, 2H),5.35 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 174.41, 163.42, 157.65, 147.73, 143.78,129.57, 127.55, 126.10, 124.43, 117.50, 116.33, 102.42, 62.40, 52.45. HRMS(ESI) [M+H] + calcd. for C 23 H 15 N5O7S: 504.0619; found: 504.0620.

[0122]

[0123] ( Ⅰ -23,C 23 H 15 N 5 O 7 S) . White sold; Yield 67%; m.p. 252.4 – 255.5 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.70 (s, 1H), 8.45 (s, 1H), 8.25 – 8.18 (m,2H), 8.01 (d, J =8.9 Hz, 1H), 7.79 (d, J=7.6 Hz, 1H), 7.69 (t, J =7.9 Hz, 1H),7.38 (s, 1H), 7.24 – 7.06 (m, 1H), 5.81 (s, 2H), 5.34 (s, 2H). 13 C NMR (126MHz, DMSO) δ 173.92, 162.95, 157.13, 147.86, 137.98, 134.80, 130.45, 127.05,125.46, 123.19, 122.84, 116.97, 115.88, 101.93, 61.91, 51.81. HRMS (ESI) [M+H] + calcd. for C 23 H 15 N5O7S: 504.0619; found: 504.0620.

[0124]

[0125] ( Ⅰ -24,C 23 H 15 N 5 O 7 S) . White sold; Yield 58%; m.p. 265.3 – 267.4 °C; 1 H NMR(500 MHz, DMSO) δ 12.45 (s, 1H), 8.78 (s, 1H), 8.36 (s, 1H), 8.16 (d, J =8.1Hz, 1H), 8.04 (d, J =8.9 Hz, 1H), 7.76 (t, J =7.6 Hz, 1H), 7.65 (t, J =7.8 Hz, 1H),7.60 (s, 1H), 7.43 (d, J =2.3 Hz, 1H), 7.19 (d, J =9.0 Hz, 1H), 7.10 (d, J =7.8 Hz,1H), 6.00 (s, 2H), 5.38 (s, 2H). HRMS (ESI) [M+H] + calcd. for C23 H 15 N5O7S:504.0619; found: 504.0622.

[0126]

[0127] ( Ⅰ -25,C 24 H 15 N 5 O 5 S) . White sold; Yield 56%; m.p. 253.4 – 257.3 °C; 1 H NMR(500 MHz, DMSO) δ 12.42 (s, 1H), 8.55 (s, 1H), 8.44 (s, 1H), 8.00 (d, J =8.7Hz, 1H), 7.86 (d, J =7.8 Hz, 2H), 7.47 (d, J =7.9 Hz, 2H), 7.35 (s, 1H), 7.14 (d, J =8.7 Hz, 1H), 5.76 (s, 2H), 5.33 (s, 2H). 13 C NMR (126 MHz, DMSO) δ 173.70,162.74, 157.02, 141.15, 132.61, 128.61, 126.91, 118.35, 115.63, 110.83,101.73, 61.72, 52.15. HRMS (ESI) [M+H] + calcd. for C 24 H 15 N5O5S: 484.0721; found:484.0722.

[0128]

[0129] ( Ⅰ -26,C 24 H 15 N 5 O 5 S) . White sold; Yield 57%; m.p. 275.9 – 278.3 °C;1 H NMR(500 MHz, DMSO) δ 12.69 – 12.17 (m, 1H), 8.73 (s, 1H), 8.42 (s, 1H), 8.01 (d, J =8.9 Hz, 1H), 7.83 (dd, J =4.6, 2.6 Hz, 2H), 7.77 – 7.52 (m, 3H), 7.38 (d, J =2.4 Hz, 1H), 7.16 (dd, J =8.9, 2.4 Hz, 1H), 5.71 (s, 2H), 5.34 (s, 2H). 13 C NMR(126 MHz, DMSO) δ 173.94, 162.99, 157.11, 137.43, 133.02, 132.06, 131.74,130.13, 127.06, 125.39, 118.40, 116.93, 115.90, 111.70, 101.94, 61.94, 51.93.HRMS (ESI) [M+H] + calcd. for C 24 H 15 N5O5S: 484.0721; found: 484.0722.

[0130]

[0131] ( Ⅰ -27,C 24 H 15 N 5 O 5 S) . White sold; Yield 63%; m.p. 261.7 – 262.9 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.61 (s, 1H), 8.41 (s, 1H), 8.01 (d, J =8.8Hz, 1H), 7.92 (d, J =7.6 Hz, 1H), 7.73 (t, J =7.7 Hz, 1H), 7.57 (t, J=7.6 Hz, 1H),7.44 – 7.36 (m, 2H), 7.19 – 7.13 (m, 1H), 5.84 (s, 2H), 5.35 (s, 2H). 13 C NMR(126 MHz, DMSO) δ 174.36, 163.42, 157.75, 139.14, 134.34, 133.89, 129.98,129.76, 127.53, 126.20, 117.45, 116.34, 111.75, 102.44, 62.34, 51.57. HRMS(ESI) [M+H] + calcd. for C 24 H 15 N5O5S: 484.0721; found: 484.0721.

[0132]

[0133] ( Ⅰ -28,C 29 H 20 N 4 O 5 S) . White sold; Yield 67%; m.p. 272.3 – 274.5 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.70 (s, 1H), 8.40 (s, 1H), 8.01 (d, J =8.9Hz, 1H), 7.65 (dd, J =11.6, 7.7 Hz, 4H), 7.46 (t, J =7.6 Hz, 2H), 7.43 – 7.33 (m,4H), 7.17 (dd, J =9.0, 2.3 Hz, 1H), 5.68 (s, 2H), 5.34 (s, 2H). 13C NMR (126 MHz,DMSO) δ 173.93, 162.99, 157.15, 140.06, 139.51, 135.07, 128.94, 128.61,127.62, 127.07, 127.04, 126.68, 125.24, 116.98, 115.92, 101.98, 61.97, 52.55.HRMS (ESI) [M+H] + calcd. for C 29 H 20 N4O5S: 535.1082; found: 535.1081.

[0134]

[0135] ( Ⅰ -29,C 29 H 20 N 4 O 5 S) . White sold; Yield 67%; m.p. 224.1 – 225.6 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.67 (s, 1H), 8.43 (s, 1H), 8.00 (d, J =8.9Hz, 1H), 7.67 – 7.59 (m, 4H), 7.46 (td, J =7.7, 2.9 Hz, 3H), 7.42 – 7.29 (m,3H), 7.15 (dd, J =8.8, 2.3 Hz, 1H), 5.70 (s, 2H), 5.33 (s, 2H). 13 C NMR (126 MHz,DMSO) δ 173.87, 162.94, 157.11, 140.64, 139.56, 136.57, 129.42, 128.94,127.67, 127.05, 127.00, 126.65, 126.51, 126.49, 115.84, 101.89, 61.91, 52.87.HRMS (ESI) [M+H] + calcd. for C 29 H 20N4O5S: 535.1082; found: 535.1082.

[0136]

[0137] ( Ⅰ -30,C 29 H 20 N 4 O 5 S) . White sold; Yield 67%; mp 261.5 – 262.7 °C; 1 H NMR(500 MHz, DMSO) δ 12.43 (s, 1H), 8.72 (s, 1H), 8.07 – 7.99 (m, 2H), 7.67 (s,1H), 7.41 (dq, J =15.5, 8.0 Hz, 6H), 7.34 (d, J =7.2 Hz, 2H), 7.29 (d, J =7.4 Hz, 1H), 7.16 (d, J =7.1 Hz, 2H), 5.56 (s, 2H), 5.29 (s, 2H). 13 C NMR (126 MHz, DMSO)δ 141.26, 132.81, 130.26, 129.00, 128.73, 128.48, 128.39, 127.96, 127.52,127.07, 125.39, 101.97, 61.89, 50.89. HRMS (ESI) [M+H] + calcd. for C 29 H 20 N4O5S:535.1082; found: 535.1083.

[0138] Example 31: Test of PTP1B enzyme inhibitory activity of the chromonethiazole dione compounds prepared in the above examples

[0139] Experimental steps:

[0140] The test solutions were dissolved in dimethyl sulfoxide (DMSO) to prepare 10 gradient concentrations: 32 μM, 16 μM, 8 μM, 4 μM, 2 μM, 1 μM, 0.5 μM, 0.25 μM, 0.125 μM, and 0.625 μM. In each well of a 384-well black-based plate, 20 μL of a mixture containing enzyme (0.29 μg / mL PTP1B) and buffer (50 mM MOPS, 2 mM DTT, and 1 mM EDTA: pH=6.5) was added. Then, 10 μL of the pre-prepared stock solution was added to each well (four replicates per group). After adding the stock solution, the 384-well plate was incubated at 37 ℃ for 15 min. Then, 20 μL of substrate (DiFMUP, 20 mM) was added to each well. Finally, the fluorescence intensity (RFU) was measured using a microplate reader.

[0141] Inhibition rate calculation formula:

[0142] ;

[0143] RFU 样品 The RFU value measured after adding the compound to a 384-well plate, reacting it with the protein, and then adding the substrate DiMUP.

[0144] RFU 空白 The RFU value was measured by adding DMSO and protein to a 384-well plate, followed by the addition of the substrate DiMUP.

[0145] Results Analysis

[0146] The PTP1B enzyme inhibitory activity of the synthesized compounds was evaluated using in vitro enzymatic experiments, and the results are shown in Table 2.

[0147] Table 2. Evaluation of the in vitro inhibitory activity of the compounds against PTP1B enzyme

[0148]

[0149] a The value is the mean ± S of the results of three independent experiments.

[0150] As shown in Table 2, the small molecule compounds provided by this invention exhibit strong binding affinity when interacting with PTP1B enzymes. Compounds containing the structures of this invention possess good PTP1B enzyme inhibitory activity; among them, the compound prepared in Example 18 exhibits the strongest PTP1B enzyme inhibitory activity, with an inhibition rate of 0.10 μM. The IC50 of the positive control drug oleanolic acid... 50 It is 5.33 μM, which is approximately 53 times that of oleanolic acid.

[0151] Example 32: Enzyme Kinetics Experiment

[0152] The inhibitory activity of the synthesized active compound against PTP1B enzyme was evaluated using in vitro enzyme kinetic experiments.

[0153] 1. Experimental Procedure

[0154] Enzyme kinetic experiments require several different concentrations of PTP1B enzyme. Therefore, this study used five different concentrations of PTP1B protein (final concentrations of 0.29, 0.58, 0.87, and 1.16 μg / mL) to conduct subsequent experiments on compound I-18, which exhibited the best activity, prepared in Example 18. First, 20 μL of a mixture containing the enzyme (0.29, 0.58, 0.87, and 1.16 μg / mL PTP1B) and buffer (50 mM MOPS, 2 mM DTT, and 1 mM EDTA, pH 6.5) was added to each well of a 384-well black plate. Then, 10 μL of the prepared stock solution was added to each well (four replicates per group). The 384-well plate was then incubated at 37°C with shaking for 15 min. Immediately after incubation, 20 μL of substrate (DiFMUP, 20 μM) was added. Finally, the fluorescence intensity (RFU) was detected using a microplate reader. The fluorescence intensity of different concentrations of the compound against PTP1B (0.29, 0.58, 0.87, 1.16 μg / mL) was measured, and a graph was plotted based on the different enzyme concentrations and the rate of change of fluorescence intensity.

[0155] 2. Results Analysis

[0156] The results of the enzyme kinetic inhibition type evaluation experiment are as follows: Figure 2 As shown. By Figure 2 It can be seen that the inhibitor binds to the enzyme via non-covalent bonds to inhibit the enzyme's activity, which is a reversible inhibitory effect.

[0157] Example 33: Substrate Dynamics Experiment

[0158] The inhibitory activity of the synthesized active compound against PTP1B enzyme was evaluated using in vitro substrate kinetic experiments.

[0159] 1. Experimental Procedure

[0160] Subsequent experiments were conducted using five different concentrations of DiMUP substrate (final concentrations of 20, 40, 60, and 80 μM) on compound I-18, the most active compound prepared in Example 18. First, 20 μL of a mixture containing enzyme (0.29 μg / mL PTP1B) and buffer (50 mM MOPS, 2 mM DTT, and 1 mM EDTA: pH=6.5) was added to each well of a 384-well black plate. Then, 10 μL of the pre-prepared stock solution of the compound was added to each well (four wells per group). After adding the stock solution, the 384-well plate was incubated at 37 °C with shaking for 15 min. Immediately after incubation, 20 μL of DiFMUP substrate (20, 40, 60, and 80 μM) was added. Finally, the fluorescence intensity (RFU) was detected using a microplate reader. The changes in fluorescence intensity at different concentrations of the compound were measured, and Lineweaver-Burk double reciprocal plots were generated based on the different substrate concentrations and their rates of change in fluorescence intensity.

[0161] 2. Results Analysis

[0162] The experimental results for evaluating the type of substrate kinetic inhibition are as follows: Figure 3 As shown, Figure 3 The in vitro substrate kinetics of PTP1B enzyme corresponding to chromonethiazolidinedione compound I-18. Figure 3 The figure in the image is a substrate dynamics diagram plotted using the double reciprocal plotting method. Figure 3 It can be seen that the inhibitors obtained through screening are mixed inhibitors.

[0163] The present invention has been described in detail above with reference to the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the spirit of the present invention.

Claims

1. A chromonethiazolidinedione compound or a pharmaceutically acceptable salt thereof, characterized in that, The chromonethiazole dione compounds have compounds as shown in formula (I): ; Wherein, R is selected from substituted or unsubstituted phenyl groups, the substitution is monosubstituted or polysubstituted, and the substituted group is selected from halogens, C 1~6 alkyl, C 1~6 alkoxy, C 1~6 Halogenated alkyl, C 1~6 The halogenated alkoxy, nitro, cyano or phenyl groups.

2. The chromonethiazolidinedione compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that, The R is selected from the following groups: 。 3. The method for preparing chromonethiazole dione compounds according to claim 1, characterized in that, Includes the following steps: Intermediate 3, A copper catalyst and a reducing agent undergo a cycloaddition reaction to yield chromonethiazole dione compounds; The structural formula of intermediate 3 is as follows: ; The definition of R is the same as that in claim 1.

4. The preparation method according to claim 3, characterized in that, The cycloaddition reaction was carried out at room temperature.

5. The preparation method according to claim 3, characterized in that, The reaction time for the cycloaddition reaction is 8-16 hours.

6. The preparation method according to claim 3, characterized in that, The intermediate 3 is prepared by the following method: Intermediate 2 and thiazolidinedione undergo aldol condensation to generate intermediate 3; The structural formula of intermediate 2 is as follows: 。 7. A pharmaceutical composition, characterized in that, Includes the chromonethiazole dione compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable excipients.

8. A protein tyrosine phosphatase 1B inhibitor, characterized in that, Includes the chromonethiazole dione compounds of claim 1 or 2, or pharmaceutically acceptable salts thereof.

9. The use of the chromonethiazole dione compound according to claim 1 or 2 in the preparation of products for the treatment and / or prevention of diabetes; said product is a pharmaceutical product.

Citation Information

Patent Citations

  • Chromone thiazole diketone compound and preparation method, pharmaceutical composition and application thereof

    CN115536653A

  • Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

    CN1774246A